Cilostazol
- Generic Name
- Cilostazol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
- Associated Therapies
- -
Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2006-11-29
- Lead Sponsor
- Shenyang Northern Hospital
- Registration Number
- NCT00404716
The Use of Cilostazol in Patients With Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 62
- Registration Number
- NCT00272831
Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
- Conditions
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 468
- Registration Number
- NCT00272454
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Ahnyang, Kyunggi Province, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Koyang, Kyunggi Province, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Sungnam, Kyunggi Province, Korea, Republic of
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2800
- Registration Number
- NCT00234065
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Joselyn Cerezo, MD
- Target Recruit Count
- 119
- Registration Number
- NCT00132743
- Locations
- 🇺🇸
Rapides Regional Medical Center, Alexandria, Louisiana, United States
🇺🇸VA Palo Alto Health Care Systems, Palo Alto, California, United States
🇺🇸The Iowa Clinic, Des Moines, Iowa, United States
Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 457
- Registration Number
- NCT00130039
- Locations
- 🇰🇷
Inje University Ilsan Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷Dongguk University International Hospital, Goyang, Kyoungki-do, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Kyunggi, Korea, Republic of
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048763
- Locations
- 🇺🇸
The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸LaRabida Children's Hospital, Chicago, Illinois, United States
🇺🇸Advanced Medical Clinical Therapeutics, Anchorage, Alaska, United States
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048776
- Locations
- 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸St. Louis University Health Sciences Center, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.